Petros Pharma Board & Executive Changes Announced
Ticker: PTPI · Form: 8-K · Filed: Oct 18, 2024 · CIK: 1815903
| Field | Detail |
|---|---|
| Company | Petros Pharmaceuticals, Inc. (PTPI) |
| Form Type | 8-K |
| Filed Date | Oct 18, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $350,000, $280,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation
TL;DR
Petros Pharma shakes up board and exec pay - new faces, new terms.
AI Summary
Petros Pharmaceuticals, Inc. announced on October 16, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. Specific details regarding the individuals involved and the financial implications of these changes are provided within the full filing.
Why It Matters
Changes in a company's leadership and executive compensation can signal shifts in strategy, operational focus, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and execution, potentially impacting the company's performance.
Key Players & Entities
- Petros Pharmaceuticals, Inc. (company) — Registrant
- October 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1185 Avenue of the Americas, 3rd Floor New York, New York 10036 (address) — Principal executive offices
- 973-242-0005 (phone_number) — Registrant's telephone number
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', suggesting shifts in key leadership positions, though specific names and roles are detailed within the full document.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on October 16, 2024.
What is the principal executive office address for Petros Pharmaceuticals, Inc.?
The principal executive office address for Petros Pharmaceuticals, Inc. is 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036.
What is the Commission File Number for Petros Pharmaceuticals, Inc.?
The Commission File Number for Petros Pharmaceuticals, Inc. is 001-39752.
What are the key items reported in this 8-K filing?
This 8-K filing reports on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers, as well as financial statements and exhibits.
Filing Stats: 640 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2024-10-18 17:00:56
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share PTPI The Nasdaq Stock Marke
- $350,000 — or's base salary from an annual rate of $350,000 to an annual rate of $280,000 effective
- $280,000 — l rate of $350,000 to an annual rate of $280,000 effective as of the Effective Date. Ex
Filing Documents
- tm2426328d1_8k.htm (8-K) — 25KB
- tm2426328d1_ex10-1.htm (EX-10.1) — 13KB
- 0001104659-24-109893.txt ( ) — 213KB
- ptpi-20241016.xsd (EX-101.SCH) — 3KB
- ptpi-20241016_lab.xml (EX-101.LAB) — 33KB
- ptpi-20241016_pre.xml (EX-101.PRE) — 22KB
- tm2426328d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 16, 2024, Petros Pharmaceuticals, Inc. (the "Company") entered into an Offer Letter Amendment (the "Amendment"), effective as of October 16, 2024 (the "Effective Date"), with Fady Boctor ("Boctor"), the Company's President and Chief Commercial Officer, for the purpose of amending that certain Employment Offer Letter, effective February 19, 2021, by and between the Company and Boctor (the "Offer Letter"). The Amendment, among other things: (i) allows Boctor to engage in other consulting or employment activities for direct or indirect remuneration, so long as such engagement or service does not create a conflict of interest with, or interfere with the performance of, his duties under the Offer Letter or conflict with any covenants with the Company; (ii) amends the term of the Offer Letter, which shall terminate on December 31, 2024; and (iii) adjusts Boctor's base salary from an annual rate of $350,000 to an annual rate of $280,000 effective as of the Effective Date. Except as expressly amended by the Amendment, the Offer Letter remains in full force and effect in accordance with the provisions thereof. The foregoing description of the material terms of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of such amendment, which is filed as Exhibit 10.1 hereto and incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Offer Letter Amendment, effective as of October 16, 2024, by and between the Company and Fady Boctor 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PETROS PHARMACEUTICALS, INC. Date: October 18, 2024 By: /s/ Fady Boctor Name: Fady Boctor Title: President and Chief Commercial Officer